March 10, 2016
Sanofi welcomes new Executive Committee member
Sanofi welcomes new Executive Committee member
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
March 10, 2016
Sanofi and MSD/Merck in joint vaccines operations in Europe
Sanofi and MSD/Merck in joint vaccines operations in Europe
March 10, 2016
Premaitha signs distribution agreement with GeNext in Russia
Premaitha signs distribution agreement with GeNext in Russia
February 2, 2016
Premaitha partners with Leeds Teaching Hositals NHS Trust to provide NIPT screening service
Premaitha Health, the developer of IONA test, has partnered with Leeds Teaching Hospitals NHS Trust to provide a private NIPT…
January 20, 2016
German Biofrontera leaving London Stock Exchange
Biofrontera, the biopharmaceutical company focusing on sun-induced skin cancer, has decided to cancel the admission of its ordinary shares to trading…
January 18, 2016
Eurostars grant awarded to international consortium including Abzena company, Antitope, for development of novel treatment for clotting disorders
Eurostars grant awarded to international consortium including Abzena company, Antitope, for development of novel treatment for clotting disorders
January 15, 2016
French drug trial disaster leaves one brain dead, five injured
One person has been left brain dead and five others have been hospitalised after taking part in a clinical trial in France of an experimental drug made by Portuguese drug company Bial, French Health Minister Marisol Touraine said on Friday.
January 6, 2016
LivaNova: “FDA’s Warning Letter can be resolved without material impact on financial results”
LivaNova said that FDA’s Warning Letter can be resolved without a material impact on financial results.
December 30, 2015
Midatech closes deal on acquiring Zuplenz
Midatech Pharma, the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, has…
December 14, 2015
AstraZeneca in talks to buy cancer drugmaker Acerta for $5 billion – WSJ
British drugmaker AstraZeneca Plc is in advanced talks to buy privately held cancer drug developer Acerta Pharma BV for more than $5 billion (£3.3 billion).